Author:
Valbert Frederik,Koppe Uwe,Schmidt Daniel,Krings Amrei,Gunsenheimer-Bartmeyer Barbara,Dröge Patrik,Ruhnke Thomas,Behrens Georg,Bickel Markus,Boesecke Christoph,Esser Stefan,Wasem Jürgen,Neumann Anja
Abstract
Abstract
Background
Despite the potentially accompanying negative clinical, epidemiologic, and health economic effects, a large proportion of persons living with the human immunodeficiency virus (HIV) are diagnosed late. Internationally, numerous diseases are known to be HIV indicator diseases. Adequate HIV testing in the presence of HIV indicator diseases could help to diagnose unknown HIV infections earlier. The objective of the HeLP study is to validate published HIV indicator diseases for the German setting and to identify guidelines in terms of these indicator diseases in order to reduce knowledge gaps and increase HIV testing when HIV indicator diseases are diagnosed.
Methods
A mixed methods approach is used. In a first step, published HIV indicator diseases will be identified in a systematic literature review and subsequently discussed with clinical experts regarding their relevance for the German setting. For the validation of selected indicator diseases different data sets (two cohort studies, namely HIV-1 seroconverter study & ClinSurv-HIV, and statutory health insurance routine data) will be analyzed. Sensitivity analyses using different time periods will be performed. Guidelines of HIV indicator diseases validated in the HeLP study will be reviewed for mentioning HIV and for HIV testing recommendations. In addition, semi-standardized interviews (followed by a free discussion) with guideline creators will identify reasons why HIV testing recommendations were (not) included. Subsequently, a random sample of physicians in medical practices will be surveyed to identify how familiar physicians are with HIV testing recommendations in guidelines and, if so, which barriers are seen to perform the recommended tests in everyday care.
Discussion
The HeLP-study adopts the challenge to validate published HIV indicator diseases for the German setting and has the potential to close a knowledge gap regarding this objective. This has the potential to improve targeted HIV testing for patients with HIV indicator diseases and consequently lead to earlier HIV diagnosis.
Trial registration
DRKS00028743
Funder
Universität Duisburg-Essen
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference28 articles.
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). PREVAILING AGAINST PANDEMICS BY PUTTING PEOPLE AT THE CENTRE: WORLD AIDS DAY REPORT. 2020. https://aidstargets2025.unaids.org/assets/images/prevailing-against-pandemics_en.pdf. Accessed 1 Mar 2022.
2. an der Heiden M, Marcus U, Kollan C, Schmidt D, Koppe U, Gunsenheimer-Bartmeyer B, Bremer V. Epidemiologisches Bulletin 47|2022. 2022. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2022/Ausgaben/47_22.pdf?__blob=publicationFile. Accessed 14 Jun 2023.
3. Sobrino-Vegas P, Moreno S, Rubio R, Viciana P, Bernardino JI, Blanco JR, et al. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004–2013. J Infect. 2016;72:587–96. https://doi.org/10.1016/j.jinf.2016.01.017
4. Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, Phillips AN, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS. 2004;18:2145–51. https://doi.org/10.1097/00002030-200411050-00006
5. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. Sexual activity without condoms and risk of HIV Transmission in Serodifferent couples when the HIV-Positive Partner is using suppressive antiretroviral therapy. JAMA. 2016;316:171–81. https://doi.org/10.1001/jama.2016.5148